DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly's - 2 James Wantuck - 2 Eli Lilly - 1 there's - 1 Julie Stich - 1 Greg Stancil - 1 you've - 1 Stancil - 1
Top related locs:
Novo U.S KFF North Carolina GLP Oslo Norway August31
Top related orgs:
Novo Nordisk - 2 Employers - 2 Accolade - 2 U.S - 1 Nordisk - 1 International Foundation of Employee - 1 Tufts Medical - 1 Medicare - 1

Search resuls for: "James Wantuck"


2 mentions found


☆ Most employer health plans don't cover new blockbuster weight loss drugs, but that's going to change
  + stars: | 2024-02-16 | by ( Cheryl Winokur Munk | ) www.cnbc.com   time to read: +10 min
Many U.S. companies are grappling with health insurance coverage issues for workers when it comes to GLP-1 drugs for weight loss. Still, many benefits experts say it's a matter of when, not if, more employers will cover GLP-1 drugs. Certainly, prescription volumes of GLP-1 weight loss drugs are soaring. Even though GLP-1 drugs are high-priced, they currently represent only 6.9% of annual claims, according to data from the International Foundation of Employee Benefit Plans. It's going to be harder and harder not to cover these drugs because the benefits seem to be so great."
Persons: Eli Lilly, there's, Julie Stich, Eli Lilly's, Greg Stancil, you've, Stancil, somebody's, James Wantuck, " Stich, Brian O'Connell, O'Connell, Wantuck, Krutika Amin, Amin Organizations: U.S, Nordisk, International Foundation of Employee, Novo Nordisk, Tufts Medical, Medicare, Healthy Aging, Scott Benefit Services, Employers, Accolade, BMI, International Foundation of, Medicaid — Locations: U.S, KFF, North Carolina, GLP, Novo
☆ U.S. employers covering weight-loss drugs could nearly double in 2024 - survey
  + stars: | 2023-10-09 | by ( ) www.reuters.com   time to read: +2 min
A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August31, 2023. The survey of 502 employers by Accolade (ACCD.O), a company that provides healthcare programs for employers, and research firm Savanta said 43% of the employers it polled could cover GLP-1 drugs in 2024 compared to 25% that cover them now. Nearly all the companies that are covering GLP-1 drugs plan to keep covering them next year, according to the survey. Employers that cover weight-loss drugs are facing a spike in their healthcare costs because of the growing popularity of Wegovy. Benefits consultant Aon (AON.N) said 1 percentage point of the 8.5% increase in employer healthcare costs it predicted for next year would be driven by employee take-up of weight-loss drugs.
Persons: Victoria Klesty, Savanta, James Wantuck, Ozempic, Eli Lilly's, Leroy Leo, Shinjini Organizations: REUTERS, Novo Nordisk, Accolade, Employers, Novo, Novo Nordisk's Wegovy, Thomson Locations: Oslo, Norway, August31, Victoria, Novo, Novo Nordisk's, United States, Bengaluru
0 next >>
Total: 2